|Bid||53.979 x 100000|
|Ask||54.051 x 100000|
|Day's range||53.510 - 53.882|
|52-week range||53.060 - 63.340|
|PE ratio (TTM)||29.08|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||N/A|
Insurers could pay $275 million (209.06 million pounds) to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit. Merck, however, has not disclosed the magnitude of its uninsured losses from the "NotPetya" attack, which disrupted production of some Merck medicines and vaccines. "Merck has not yet fully quantified its losses, much less given any of its insurers an estimate of the total amount of those losses," Merck spokeswoman Claire Gillespie said in a statement.
Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services unit. ...
The Merck Foundation has launched a five-year initiative: Bridging the Gap: Reducing Disparities in Diabetes Care to help improve diabetes care and health outcomes for vulnerable and underserved populations in the United States.
Is Wall Street underestimating Keytruda? Shares of Merck& Co. ( MRK) popped today after Citigroup’s Andrew Baum upgraded the drug maker to Buy from Neutral, and hiked his price target from $65 a share to $72 a share, citing heightened expectations for the blockbuster cancer drug. It’s been a volatile 2017 for Merck.
AstraZeneca and Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted and granted priority review for a supplemental New Drug Application for the use of LYNPARZA® tablets in patients with germline BRCA-mutated , HER2-negative metastatic breast cancer who have been previously treated with chemotherapy either in the neoadjuvant, ...
Merck , known as MSD outside the United States and Canada, today announced the presentation of updated overall survival findings, a secondary endpoint, from the phase 3 KEYNOTE-024 trial evaluating KEYTRUDA® , the company’s anti-PD-1 therapy, as a first-line monotherapy in patients with non-small cell lung cancer whose tumors express high levels of PD-L1 .
To help support innovation in cancer research, Merck , known as MSD outside the United States and Canada, today announced that the company will make a $3 million charitable contribution to Swim Across America.
Merck , known as MSD outside of the United States and Canada, today announced a collaboration with the American Liver Foundation to raise awareness among U.S. veterans about their increased risk for chronic hepatitis C virus infection.
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
Merck , known as MSD outside the U.S. and Canada, today announced that the company will not submit applications for regulatory approval for anacetrapib, Merck’s investigational cholesteryl ester transfer protein inhibitor.
Merck , known as MSD outside of the United States and Canada, announced results from final analyses of the pivotal Phase III efficacy, immunogenicity, and safety clinical trial for GARDASIL® 9 .
KENILWORTH, N.J.--(BUSINESSWIRE)-- Merck’s 20-year commitment to HPV research highlighted in oral session Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced results from ...
Global Healthcare Investment Advisors LLC wants to generate more than just healthy financial returns with its deals. The New York-based firm, which does business as the Global Health Investment Fund, also ...
Merck , known as MSD outside the United States and Canada, today announced that researchers will provide 40 scientific data presentations on the company’s established and investigational infectious disease medicines and vaccines at ID Week 2017 in San Diego from Oct.
Merck , known as MSD outside of the United States and Canada, today announced that data from the company’s chronic hepatitis C clinical development programs and real-world studies are scheduled to be presented at The Liver Meeting® 2017.
Merck, a leading science and technology company, will invest € 35 million in a new production line for the aseptic filling of biotech medicines under isolator at its manufacturing site of Bari, Italy. The announcement was made as part of an event celebrating the 25th anniversary of the site and its leading role on the science and technology scene in the South Italian region of Apulia. "This investment underpins the importance of the Modugno-Bari production site for our growing Healthcare business," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
Merck & Co. is halting development of new hepatitis C treatments after reviewing their effectiveness and determining an abundance of treatments were already available.
Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.
Merck & Co. said Friday it would discontinue the development of the investigational combination regimens MK-3682B and MK-3682C for the treatment of chronic hepatitis C, after a review of available Phase ...
WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESSWIRE)-- Updated Data to be Presented at ESMO 2017 Congress Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and ...
KENILWORTH, N.J.--(BUSINESSWIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from all three cohorts of the registrational, phase 2 KEYNOTE-059 ...
Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time.